Discovery of potent parasite protein may lead to new therapeutic options for inflammatory bowel conditions

November 24, 2017
High magnification micrograph of Crohn's disease. Biopsy of esophagus. H&E stain. Credit: Nephron/Wikipedia

A single protein from a worm parasite may one day offer new therapeutic options for treating inflammatory bowel diseases like Crohn's or Ulcerative Colitis, that avoid the potentially serious side effects of current immunosuppressant medications.

The study, published today in Nature Communications, demonstrates the discovery of a distinct new worm protein which mimics a cytokine found in humans, known as transforming growth factor-beta (TGF-β).

The newly-discovered protein switches off inflammation by inducing "regulatory T cells", the body's own means of dampening excessive reactivity.

The "Hygiene Hypothesis" suggests that some bugs and parasites may protect you from an overly-reactive immune system, which can cause allergy and other disorders. Harnessing this route of immune regulation is potentially a much safer option than our currently-available medications can offer.

First author Dr Danielle Smyth, Research Associate in Parasitology at the Institute of Infection, Immunity and Inflammation, said: "Discovering a new protein that can potently induce regulatory T cells (Tregs) from is unexpected and very exciting in terms of finding a new potential biologic for inflammation conditions."

Inflammatory bowel diseases are made up of many variations, and each patient requires to be treated in an individual manner. As such, treatment approaches are being explored such as T cell therapy (taking a patient's T cells and converting them to Tregs and giving them back to the patient).

Dr Smyth added: "We hope to explore this option and see whether the Tregs our parasite molecule induce offer a regulatory advantage over current treatments."

Rick Maizels, Professor of Parasitology at the Institute, said: "The next horizon for these exciting findings will be to test whether the new can be used to treat inflammatory diseases, reaping the benefits of the 'hygiene hypothesis' and dispensing with the themselves."

The paper, 'A structurally distinct TGF-β mimic from an intestinal helminth parasite potently induces regulatory T cells' is published in Nature Communications.

Explore further: Cytokine controls immune cells that trigger inflammatory bowel disease, study finds

More information: Chris J. C. Johnston et al. A structurally distinct TGF-β mimic from an intestinal helminth parasite potently induces regulatory T cells, Nature Communications (2017). DOI: 10.1038/s41467-017-01886-6

Related Stories

Cytokine controls immune cells that trigger inflammatory bowel disease, study finds

April 18, 2017
A certain cytokine, or small protein that helps cells communicate during immune responses, can control whether immune cells promote or suppress inflammatory bowel disease, a finding that could lead to new treatments, according ...

Innate lymphoid cells play an important role in regulation of intestinal inflammation

August 28, 2017
The intestine contains an extensive and diverse microbial biome, a population that includes potential pathogens and dietary antigens that need to be tolerated. Dysregulation of mucosal responses may cause a loss of tolerance, ...

Immune and nerve cells work together to fight gut infections

September 7, 2017
Nerve cells in the gut play a crucial role in the body's ability to marshal an immune response to infection, according to a new study from Weill Cornell Medicine scientists.

Latest research offers hope for patients with inflammatory diseases

January 19, 2017
University of Queensland researchers have discovered a molecular trigger for inflammation that could lead to new treatments for rheumatoid arthritis, inflammatory bowel disease and neurodegenerative diseases.

The swollen colon—cause of chronic inflammation discovered

April 28, 2017
Researchers at the University Medical Center of Johannes Gutenberg University Mainz and the German Research Center for Environmental Health, Helmholtz Zentrum München have discovered that too much of the oncogene Bcl-3 leads ...

New target could soothe the itch of inflammatory skin conditions

July 17, 2017
Existing medicines could offer a new way to treat inflammatory skin conditions, researchers at the Walter and Eliza Hall Institute and the Royal Melbourne Hospital have revealed.

Recommended for you

The immune cells that help tumors instead of destroying them

December 12, 2017
Lung cancer is the leading cause of cancer-associated deaths. One of the most promising ways to treat it is by immunotherapy, a strategy that turns the patient's immune system against the tumor. In the past twenty years, ...

Cancer gene plays key role in cystic fibrosis lung infections

December 12, 2017
PTEN is best known as a tumor suppressor, a type of protein that protects cells from growing uncontrollably and becoming cancerous. But according to a new study from Columbia University Medical Center (CUMC), PTEN has a second, ...

Researchers bring new insight into Chediak-Higashi syndrome, a devastating genetic disease

December 12, 2017
A team of researchers from the National Institutes of Health and University of Manchester have uncovered new insights into a rare genetic disease, with less than 500 cases of the disease on record, which devastates the lives ...

Drug increases speed, safety of treatment for multiple food allergies

December 11, 2017
In a randomized, controlled phase-2 clinical trial, an asthma medication increased the speed and safety of a protocol used to treat children for several food allergies at once, according to a study by researchers at the Stanford ...

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

December 9, 2017
Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening ...

Location, location, location: Immunization delivery site matters

December 1, 2017
In vaccination, a certain subpopulation of dendritic cells is vital to triggering the body's adaptive immune system, report researchers at The Jackson Laboratory (JAX), Yale University and Astra-Zeneca.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.